Fatal cerebral haemorrhage after COVID-19 vaccine

Previously healthy woman in her thirties develops headaches one week after vaccination with ChAdOx1 nCoV-19, is admitted in the emergency department with slurred speech, uncoordinated movements and reduced consciousness, dies from thrombocytopenia. Post mortem examination reveals antibodies to PF4 and fresh small thrombii the transverse sinus, frontal lobe and pulmonary artery.


Fatal cerebral haemorrhage
after COVID-19 vaccine

Comments

Post a Comment

Popular posts from this blog

Exacerbation of COPD after a COVID 19-Booster Vaccine

Image
A 75-year-old African American woman presented to the Emergency Department (ED) complaining of shortness of breath, cough and a drop in her oxygen saturation (SpO2) from her baseline of 95%–88%.  She received a Pfizer COVID 19 booster vaccine one day before her symptoms began. The patient had received the Johnson & Johnson COVID-19 vaccine 11 months prior without a notable reaction.    She had a history of  chronic obstructive pulmonary disease (COPD)  but was  not on any home oxygen.  Upon admission the patient had an SpO2 of 82% and a heart rate of 101 beats per minute. Notably, she was afebrile, with a temperature of 36.6 °C. On physical exam the patient was noted to be wheezing and breathing with difficulty. She t ested negative for a variety of respiratory viruses including COVID-19.  A chest radiograph (x-ray) demonstrated subtle patchy opacifications consistent  with a COPD exacerbation, and no consolidations or pleural effusions....
Read more

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis ...
Read more

Clouds Shift Again: Stratus Dominates, Cicada Stirs

Image
In summer 2025, the Nimbus (NB.1.8.1) and Stratus (XFG) variants were competing for dominance (see previous post  Nimbus and Stratus: Cloudy With a Chance of Covid ). By that point, earlier JN.1-descended variants such as LP.8.1 had already been largely displaced. That competition is now largely settled, with Stratus and its descendants firmly in the lead across most regions. As of early January 2026, Stratus (XFG) and its descendants dominate globally. In the U.S., sequencing and wastewater data show XFG making up 60–70% of cases, and when its sublineages (XFG.14.1, XFG.1, XFG.6) are included, the total reaches ~80% by late December. Nimbus has fallen sharply and now accounts for roughly 5% of sequenced cases. The new variant to watch is BA.3.2 nicknamed “Cicada”. Unlike recent variants that evolved incrementally from JN.1, BA.3.2 represents a larger evolutionary jump. It's a descendant of early Omicron BA.3, a lineage that largely disappeared in 2022. Cicada was designated by WHO...
Read more